Laboratorios Farmaceuticos Rovi clears its cost of capital, but the record is mixed across the five tests. Real value creation, just not yet consistent.
Health DiagnosticsCardiovascularPain ManagementRespiratoryUrologyOsteoporosisCentral Nervous SystemBiopharmaBiotechnologyChemicalManufacturingPharmaceutical
Description
Laboratorios Farmaceuticos Rovi, S.A. is a company focused on developing, manufacturing, and marketing high-quality pharmaceutical products. It holds a significant position in the pharmaceutical industry, engaging primarily in the production of activ…
Analysis
Middle-of-the-road
Laboratorios Farmaceuticos Rovi, S.A. is a middle-of-the-road business: neither the economics nor the price stand out from the peer group.
The price is expensive. You pay 32.5× its owner earnings: the cash an owner could take out each year, which is in the historically expensive zone. At today's price, the market is assuming roughly 13% yearly growth; analysts expect 15%. The price, in other words, assumes less than the experts do.
The trajectory is tepid and the balance sheet is sturdy. The company scores 12/20 on our value-creation score: creating some value. Analyst sentiment is cautious.
Nothing is flagged here: no red or amber gates, no divergence between profits and cash. That is itself information: the numbers are straightforward. As always: this describes the company's numbers; it is not a recommendation.
360° rank · history
1007550250
Jan 202380
65
2023202420252026
All-time high
84
Mar 2026
All-time low
15
Jan 2025
Average rank
64
across all years
Detailed & Historical Ranks
Deep dive into 15 detailed ranks and 3 years of history.
Current202520242023
Price/Sales
56
26
33
40
Price/Earnings
31
40
38
49
Price/Book
46
19
22
17
Dividend Yield
65
58
63
72
Value (overall)
61
24
35
42
Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.